Reply: An incomplete story
Beta-blockers reduced mortality in landmark, placebo-controlled trials of heart failure with a reduced left ventricular ejection fraction only for those in sinus rhythm rather than atrial fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% of target) and similar heart...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2018
|
| Summary: | Beta-blockers reduced mortality in landmark, placebo-controlled trials of heart failure with a reduced left ventricular ejection fraction only for those in sinus rhythm rather than atrial fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% of target) and similar heart rate reductions (1). For patients in AF, neither baseline nor follow-up ventricular rate was associated with beta-blocker benefit, nor have trials comparing rate control intensity shown important differences in outcome, although slower rates may be associated with a worse prognosis (2). |
|---|